de Semir David, Petriz Jordi, Avinyó Anna, Larriba Sara, Nunes Virginia, Casals Teresa, Estivill Xavier, Aran Josep M
Centre de Genètica Mèdica i Molecular, Institut de Recerca Oncològica, Hospital Duran i Reynals, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.
J Gene Med. 2002 May-Jun;4(3):308-22. doi: 10.1002/jgm.264.
Chimeraplasty is a novel methodology that uses chimeric RNA/DNA oligonucleotides (chimeraplasts) to stimulate genomic DNA repair. Efficient uptake and nuclear localization of intact chimeraplasts are key parameters to achieve optimal correction of mutation defects into specific cell types.
A 5'-end FITC-labeled 68-mer RNA/DNA oligonucleotide was complexed with the polycation polyethylenimine (PEI) and the cationic lipids Cytofectin and GenePorter. Flow cytometry was employed to evaluate chimeraplast uptake under different conditions. Intracellular chimeraplast distribution and co-localization with endocytosis markers were assessed by confocal microscopy. Relative quantification of chimeraplast metabolism was performed by denaturing PAGE and GeneScan(trade mark) analysis.
In airway epithelial cells, optimized chimeraplast uptake reached near 100% efficiency with the carriers tested. However, chimeraplast nuclear localization could only be achieved using PEI or Cytofectin. Chimeraplast/GenePorter lipoplexes were retained in the cytoplasm. PEI polyplexes and Cytofectin lipoplexes displayed different uptake rates and internalization mechanisms. Chimeraplast/PEI polyplexes were internalized at least partially by fluid-phase endocytosis. In contrast, phagocytosis may have contributed to the internalization process of large-sized chimeraplast/Cytofectin lipoplexes. Moreover, significant chimeraplast degradation was detected 24 h after transfection with both PEI polyplexes and Cytofectin lipoplexes, although the latter seemed to confer a higher degree of protection against nuclease degradation.
Both Cytofectin and PEI are efficient for chimeraplast nuclear uptake into airway epithelial cells. However, despite the distinct structures and trafficking pathways of the corresponding complexes, none of them could prevent nuclease-mediated metabolism of the chimeric oligonucleotides. These findings should be taken into account for future investigations of chimeraplast-mediated gene repair in airway epithelial cells.
嵌合体修复术是一种利用嵌合RNA/DNA寡核苷酸(嵌合体)刺激基因组DNA修复的新方法。完整的嵌合体有效摄取和核定位是在特定细胞类型中实现突变缺陷最佳校正的关键参数。
将5'-末端异硫氰酸荧光素(FITC)标记的68聚体RNA/DNA寡核苷酸与聚阳离子聚乙烯亚胺(PEI)以及阳离子脂质细胞转染试剂(Cytofectin)和基因转运体(GenePorter)复合。采用流式细胞术评估不同条件下嵌合体的摄取。通过共聚焦显微镜评估细胞内嵌合体分布以及与内吞标记物的共定位。通过变性聚丙烯酰胺凝胶电泳(PAGE)和基因扫描(GeneScan™)分析对嵌合体代谢进行相对定量。
在气道上皮细胞中,使用所测试的载体,优化后的嵌合体摄取效率接近100%。然而,只有使用PEI或细胞转染试剂(Cytofectin)才能实现嵌合体的核定位。嵌合体/基因转运体(GenePorter)脂质体复合物保留在细胞质中。PEI多聚体和细胞转染试剂(Cytofectin)脂质体复合物表现出不同的摄取速率和内化机制。嵌合体/PEI多聚体至少部分通过液相内吞作用内化。相比之下,吞噬作用可能促成了大型嵌合体/细胞转染试剂(Cytofectin)脂质体复合物的内化过程。此外,在用PEI多聚体和细胞转染试剂(Cytofectin)脂质体复合物转染24小时后均检测到明显的嵌合体降解,尽管后者似乎对核酸酶降解具有更高程度的保护作用。
细胞转染试剂(Cytofectin)和PEI对于将嵌合体核摄取到气道上皮细胞中均有效。然而,尽管相应复合物的结构和运输途径不同,但它们均无法防止核酸酶介导的嵌合寡核苷酸代谢。在未来气道上皮细胞中嵌合体介导的基因修复研究中应考虑这些发现。